Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study - 18/03/25
, Eleni Rapsomaniki, PhD b, Antonio Anzueto, MD c, Kirsty Rhodes, PhD b, Nathaniel M. Hawkins, MD d, Claus F. Vogelmeier, MD e, Jonathan Marshall, PhD f, Hana Müllerová, PhD gAbstract |
Background |
Patients with chronic obstructive pulmonary disease (COPD) have elevated cardiopulmonary and mortality risk, particularly following exacerbations. While single inhaler triple therapies (SITTs), such as budesonide/glycopyrrolate/formoterol fumarate (BGF), reduce cardiopulmonary risk versus dual bronchodilator therapy, there is limited evidence comparing outcomes with SITTs versus multiple inhaler triple therapies (MITTs).
Methods |
SKOPOS-MAZI was a retrospective comparative effectiveness study in patients with COPD aged ≥40 years using US administrative claims data from Optum's deidentified Clinformatics® Data Mart Database. The primary and secondary endpoints were time to all-cause mortality and time to first severe cardiopulmonary event following initiation of BGF or MITT (identification period: October 1, 2020-June 30, 2023; index date: first prescription fill). Relative hazards of outcomes were assessed until a censoring event using Cox proportional hazards models, with inverse propensity treatment weighting accounting for between-group imbalances (standardized mean difference >0.1) in baseline characteristics.
Results |
In the primary cohort, risk (hazard ratio [95% confidence intervals]) of all-cause mortality and a first severe cardiopulmonary event were 18% (0.82 [0.75, 0.91]) and 12% (0.88 [0.83, 0.93]) lower in patients initiating BGF versus MITT; results were consistent across censoring definitions, landmark periods, and sensitivity cohorts.
Conclusion |
In this real-world comparative effectiveness study of patients with COPD initiating BGF or MITT, BGF was associated with lower all-cause mortality and severe cardiopulmonary event risk versus MITT after accounting for between-group differences in baseline sociodemographic and clinical characteristics. This study supports the benefits of BGF over MITT and the need to consider proactive use of SITTs in COPD management.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Key words : All-cause mortality, Budesonide/glycopyrrolate/formoterol fumarate, Cardiopulmonary, Chronic obstructive pulmonary disease, Comparative effectiveness study, Multiple inhaler triple therapy, Real-world evidence, Single inhaler triple therapy
Plan
| Funding: The SKOPOS-MAZI study was supported by AstraZeneca. The sponsor was involved in the study design; the collection, analysis, and interpretation of data; the writing of the report; and in the decision to submit the article for publication. Medical writing support for development of this manuscript was funded by AstraZeneca. |
|
| Conflict of Interest: Michael Pollack, Eleni Rapsomaniki, Kirsty Rhodes, Jonathan Marshall, and Hana Müllerová are employees of AstraZeneca and may hold stock and/or stock options in the company. Antonio Anzueto is a consultant for AstraZeneca, GlaxoSmithKline, Viatrix, Sanofi/Regeneron, Novartis, and Boehringer-Ingelheim. Nathaniel Hawkins is a consultant and speaker and has received research grants from AstraZeneca. Claus Vogelmeier has conducted presentations at symposia and/or participation in scientific advisory boards for Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols, Insmed, MedUpdate, Menarini, Novartis, Nuvaira, Roche, and Sanofi. |
|
| Authorship: All authors had access to the study data and made a significant contribution to the data reported. MP: Writing – review & editing, Visualization, Supervision, Project administration, Methodology, Investigation, Formal analysis, Conceptualization; ER: Writing – review & editing, Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization; AA: Writing – review & editing, Visualization, Investigation, Data curation, Conceptualization; KR: Writing – review & editing, Visualization, Methodology, Investigation, Formal analysis, Conceptualization; NMH: Writing – review & editing; CFV: Writing – review & editing, Visualization; JM: Writing – review & editing, Supervision, Conceptualization, HM: Writing – review & editing, Supervision, Methodology, Conceptualization |
Vol 138 - N° 4
P. 650 - avril 2025 Retour au numéro
Article précédent
- Lower Risk of Death and Kidney Failure Associated with Higher Target (vs Below-Target) Doses of RAS Inhibitors in Octogenarians with HFrEF
- Mo-Kyung Sin, Richard M. Allman, Charles Faselis, Wilbert S. Aronow, Cynthia J. Brown, Phillip H. Lam, Wen-Chih Wu, Qing Zeng-Treitler, Samir S. Patel, Venkatesh K. Raman, Sijian Zhang, Helen M. Sheriff, Charity J. Morgan, Paul A. Heidenreich, Gregg C. Fonarow, Ali Ahmed
- Creative Arts Therapy Reduces Psychological Distress in Nonpatient-Facing Healthcare Workers
- Rafaela Avallone Mantelli, Jeri Forster, Katherine Reed, Anthony Edelblute, Michael Henry, Hillary Sinn, Marc Moss
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?